Comparative antibiotic activity versus vancomycin intermediate-susceptible Staphylococcus aureus

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 151-153

  Huband, Michael D ^a,b   Cohen, M A ^a   Gage, J W ^a   VanderRoest, S R ^a  

^a PFIZER INC   (United States)

^b Warner Lambert/Parke Davis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; CONFERENCE PAPER; MOUSE; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ANIMALIA; STAPHYLOCOCCUS AUREUS;

EID: 0032706188     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00040     Document Type: Conference Paper

References (15)

1. Hiramatsu K. Update on vancomycin-resistant Staphylococcus aureus. Antibiotics Chemother 1997; 1: 5
2. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3
3. Hiramatsu K. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR 1997; 46: 624-6
4. Robinson-Dunn B, Jennnings G, Mitchell J. Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus (VISA) [abstract LB-14]. Paper presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 29; Toronto, Ontario
5. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6
6. Martin R. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 1997; 46: 765-6
7. Martin R, Campbell C, Ellis H. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 1997; 46: 813-5
8. Shonekan D, Handwerger S, Mildvan D. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. J Antimicrob Chemother 1997; 39: 405-9
9. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard, M7-A4. Wayne, PA: NCCLS. January 1997
10. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents, M26-T. Wayne, PA: NCCLS, September 1992
11. 50 and its error by means of logarithmic-probit paper. Proc Soc Exp Biol Med 1944; 57: 261-4
12. Shimizu M, Sekine Y, Higuchi H, et al. Piromidic acid, a new antibacterial agent; absorption, distribution, excretion, and metabolism. Antimicrob Agents Chemother 1970; 10: 128-8
13. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; eighth informational supplement, M100-S8. Wayne, PA: NCCLS, January 1998
14. Livermore DM, Warner M, Cookson BD. Detecting vancomyein-intermediate Staphylococcus aureus: increased vigilance required by European microbiologists. Eurosurveillance Weekly 1998 Jan 8
15. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-7